Back to Portfolio
MOH

Molina Healthcare

$153 7.8B market cap April 15, 2026 (Refreshed from March 15, 2026)
🎧 Audio Deep Dive
Listen to the full educational narration of this analysis
0:00 --:--
Molina Healthcare Inc MOH BUFFETT / MUNGER / KLARMAN SUMMARY
1 SNAPSHOT
Price$153
Market Cap7.8B
2 BUSINESS

Molina Healthcare at $153 is a pure-play Medicaid managed care operator at 8.5x normalized earnings with >$11/share contracted embedded earnings, trading 10% below Klarman's entry price. The 57% decline from $360 prices in permanent impairment, but the evidence shows a cyclical rate trough: Medicaid produces 2% pretax margin normalized, January rates are modestly above trend (first positive signal), and the Florida CMS sole-source contract ($6B annual) is transformational. Share count is down 12%, amplifying recovery EPS. Price tested $121-131 support twice and held, defining downside. Probability-weighted fair value of $215-290 offers 29-47% upside with Investor Day May 8 as a near-term catalyst. Target 2-4% allocation.

3 MOAT NARROW

State Medicaid contract incumbency (90% renewal win rate), 6.3% G&A ratio (industry-best), 44 years Medicaid expertise, $50B+ RFP pipeline, Florida CMS sole-source contract

4 MANAGEMENT
CEO: Joseph Zubretsky

Mixed -- $1B buybacks during negative FCF year (poor timing) but strategic discipline shown in Marketplace reduction, MAPD exit, and aggressive contract wins. Long-term track record strong: revenue 2.4x, stock 6x from 2017 lows.

5 ECONOMICS
1.7% Op Margin
8.5% ROIC
11.6% ROE
32.4x P/E
-0.64B FCF
-7% Debt/EBITDA
6 VALUATION
FCF Yield10.8%
DCF Range215 - 290

Undervalued by 29-47% vs probability-weighted fair value of $215-$290

7 MUNGER INVERSION
Kill Event Severity P() E[Loss]
Medicaid rate timing -- 300-400 bps underfunding, but January cycle shows rates 'modestly in excess of trend' for first time HIGH - -
Federal Medicaid policy risk -- Big Beautiful Bill passed, block grants remain theoretical but not enacted MED - -
8 KLARMAN LENS
Downside Case

Medicaid rate timing -- 300-400 bps underfunding, but January cycle shows rates 'modestly in excess of trend' for first time

Why Market Right

Federal Medicaid funding cuts or block grant conversion; Florida CMS execution risk -- $6B new contract, new population, complex; Q1 2026 earnings miss could retest $131 support; ACA enhanced subsidy expiration reducing Marketplace membership; Second consecutive year of negative FCF would be concerning

Catalysts

Investor Day May 8, 2026 -- long-term goals, growth playbook, potential guidance lift; Medicaid rate recovery: January cycle covers 60% of premium, rates modestly above trend; Florida CMS sole-source $6B contract go-live late 2026 -- largest win in company history; Embedded earnings >$11/share from FL, GA, TX, WI, Medicare duals; MAPD exit 2027 removes money-losing segment; Share count down 12% (50.8M from 57.7M) -- amplifies recovery EPS; M&A pipeline growing as smaller MCOs seek exits in challenging environment

9 VERDICT ACCUMULATE
B+ Quality Moderate -- $4.25B cash offsets $3.95B debt. Negative FCF in 2025 was aberrant; 5yr avg FCF is $842M. Leverage rose but manageable for insurance company.
Strong Buy$135
Buy$153
Fair Value$290

ACCUMULATE at current $153 (8.5x normalized). Strong Buy below $135 (7.5x). Hold for margin recovery and embedded earnings harvest through 2027-2028.

🧠 ULTRATHINK Deep Philosophical Analysis

MOH - Ultrathink Analysis (Refreshed April 2026)

A Buffett/Munger/Klarman meditation on Molina Healthcare at $153

The Core Question: Is the Cycle Turning?

When we first analyzed Molina in March at $149, the question was whether this was a cyclical trough or structural decline. A month later, the evidence has shifted meaningfully in favor of the cyclical thesis.

The Q4 2025 earnings call delivered three critical data points that were not available in March. First, management stated that January 2026 Medicaid rates -- covering 60% of annual premium revenue -- are "modestly in excess of trend." This is the first time in this cycle that rates have exceeded medical cost trend. In an actuarially-driven business, this is not a trivial observation. It is the mathematical precondition for margin recovery. Second, embedded earnings have risen from $8.65 to over $11 per share, driven primarily by the Florida CMS sole-source contract worth $6 billion annually. Third, management explicitly called 2026 "the trough for managed Medicaid margins."

Seth Klarman does not make 2% portfolio bets on businesses in permanent decline. He buys distressed assets with margin of safety and identifiable catalysts for value realization. His average cost of approximately $173 per share means he is underwater at $153, which is itself instructive. Klarman does not panic-sell when positions move against him. He adds. The question for independent investors is whether the facts justify the same conviction.

The GEICO Analogy Revisited: From Theory to Evidence

In March, we examined Burry's comparison of Molina to "early GEICO" with appropriate skepticism. The G&A advantage, we noted, comes from focus rather than structure, making it narrower than GEICO's permanent cost advantage from eliminating agent commissions.

But the analogy gains strength when you examine what is happening to Molina's competitors. The company's 6.3% G&A ratio in Q3 2025 is not merely a talking point -- it is the difference between survival and distress. When Medicaid is underfunded by 300-400 basis points, a company with 6.3% G&A can still earn a low-single-digit pretax margin. A competitor with 8.5% G&A is losing money. A competitor with 12% G&A is hemorrhaging.

This is precisely the dynamic Zubretsky described on the Q4 call: "The current challenging operating environment is a catalyst for many smaller and less diverse health plans to consider their strategic options." Translation: weaker competitors are coming to Molina looking to sell, because they cannot survive the trough. Molina is not merely weathering the storm -- it is using the storm to acquire distressed assets at favorable prices. This is the playbook of every great insurance operator from GEICO to Fairfax: survive the hard market, use superior capitalization to grow, then reap the rewards when the cycle turns.

The RFP win rates confirm this competitive advantage is real and measurable: 90% on renewals, 80% on new contracts. Those are not the win rates of a company in structural decline.

The Government Customer Paradox: New Dimensions

Munger's insight about the government customer paradox remains valid, but the Q4 earnings call added nuance worth examining.

The conventional view is that government customers are capricious price-setters who can crush MCO margins at will. The California retroactive rate action in Q4 2025 -- which cost Molina roughly $2 per share -- seemed to confirm this fear. But look at what happened next: the January 2026 rate cycle, covering the majority of revenue, came in modestly above trend. Why?

Because the system is self-correcting. When rates are set below actuarial soundness for long enough, MCOs begin exiting markets, provider networks deteriorate, and state Medicaid agencies face the unpleasant reality that their rate-setting has undermined the program they are supposed to administer. Federal law requires actuarial soundness. States cannot indefinitely set rates below cost without facing legal challenges, plan exits, and degraded service quality for their most vulnerable populations.

This is not wishful thinking. It is the historical pattern, repeated through multiple cycles over 40 years of Medicaid managed care. The 2025-2026 trough is severe but not unprecedented. The 2017-2018 trough saw Molina report a net loss of $512 million. The company survived, margins recovered, and the stock rose from $45 to $424 over the subsequent seven years.

The real question Munger would ask is not "can the government crush this business?" but rather "what are the odds that American society eliminates the intermediary role of private MCOs in serving 85 million Medicaid beneficiaries?" The answer is: very low in any foreseeable political environment. Neither party has the votes or the infrastructure to bring Medicaid administration in-house across 50 states.

The Embedded Earnings Puzzle: Is $11/Share Real?

This is where independent scrutiny matters most. Management claims embedded earnings of over $11 per share, representing future contract revenue at target margins from signed or won contracts not yet at scale. Is this credible?

The Florida CMS sole-source contract is the centerpiece. At $6 billion of annual premium and a 4-5% pretax margin target, this single contract represents roughly $5-6 per share of embedded EPS once fully ramped. The contract is signed. It is sole-source (no competition). The go-live is late 2026. The only question is execution speed.

Georgia ($2B), Texas, Wisconsin, and Medicare duals conversions account for the remainder. These are also signed or won contracts with defined implementation timelines.

The credibility check: Molina's historical track record of ramping new contracts to target margins within 2-3 years. The company has done this successfully in California, Michigan, Ohio, and numerous other states over decades. The operational playbook is proven. Florida CMS is larger than any single prior contract, which introduces execution risk, but Molina's 44-year Medicaid operating history provides confidence that the organization can handle the complexity.

The risk is not whether these contracts will generate revenue -- they will, contractually. The risk is whether Molina can manage the MCR to target levels in the first 1-2 years. Historical precedent says yes, with some initial implementation drag (management guided $1.50/share for Florida in 2026). The prudent assumption is 60-80% realization of the $11+ embedded earnings by 2028, yielding $7-9 per share of incremental EPS.

The Valuation Question: What Are You Really Paying?

At $153, the market capitalization is $7.77 billion. Cash on the balance sheet is $4.25 billion. Total debt is $3.95 billion. Enterprise value is roughly $7.47 billion.

On $45 billion of revenue, you are paying 0.17x revenue. On $842 million of normalized free cash flow (5-year average), you are paying 8.9x FCF. On normalized EPS of $18-22, you are paying 7-8.5x earnings.

But these are backward-looking metrics. The forward picture, incorporating embedded earnings and rate recovery, suggests 2028 EPS power of $20-28. At $153 today, you are paying 5.5-7.7x 2028 earnings for a business that historically traded at 14-18x.

The margin of safety framework:

  • Book value: $80/share. At $153, you pay 1.91x tangible book. Adequate but not extreme.
  • Liquidation value: Cash ($4.25B) + receivables (~$3.5B) - all liabilities ($11.5B) = negative, so no asset-based floor. This is an operating business that must earn its way.
  • Normalized earnings power: $18-22/share at 12-14x = $216-$308. Margin of safety: 29-50%.
  • Full recovery with embedded: $25-28/share at 14-16x = $350-$448. Margin of safety: 56-66%.

Klarman's framework demands at least 30-40% margin of safety. At $153 versus a probability-weighted fair value of $215-$290, the margin of safety is 29-47%. This is why he bought at $173 and presumably would add at $153.

The Patient Investor's Path (Updated)

The staged approach from March needs revision given new information:

Stage 1 (Current, $153): Begin accumulating. The thesis has strengthened materially. Price has tested $121-131 twice and held. Rates are turning. Embedded earnings have grown. Investor Day May 8 is an approaching catalyst. Size at 1-2% of portfolio.

Stage 2 ($135 or below): Aggressive accumulation. At 7.5x normalized earnings, the margin of safety exceeds 40%. Florida execution risk and rate timing uncertainty are adequately compensated. Size up to 3-4%.

Stage 3 (Margin recovery confirmed, $180+): Hold for re-rating. As quarterly MCR data improves and embedded earnings begin appearing in reported results, the market will re-rate. Hold through $250-$350.

Stage 4 ($300+): Begin trimming. At 14-16x normalized earnings, the stock approaches fair value. Cyclical recovery trades have a natural endpoint.

The holding period is 2-3 years. The catalyst sequence is: Investor Day (May 2026) confirms long-term targets, 2H 2026 rate improvements show in quarterly MCR data, Florida CMS begins contributing in 2027, and by 2028 normalized EPS power becomes visible to the market.

The patient investor's edge here is willingness to hold through a 2026 trough year where reported EPS looks terrible but underlying business fundamentals are improving. When the headline P/E is 30x trough earnings, most investors cannot own it. When the normalized P/E is 8.5x with 12% fewer shares and $11+ of embedded earnings on the way, value investors should be buying.

"The essence of investment management is the management of risks, not the management of returns." -- Benjamin Graham

"You can't make a good deal with a bad person." -- Warren Buffett. At $153 with Klarman and Burry as co-investors, you are in good company.

Executive Summary

Molina Healthcare is a pure-play government-sponsored managed care company operating Medicaid, Medicare, and ACA Marketplace health plans across 20 states. The stock remains down ~57% from its April 2025 high of $359.97. Since our March analysis at $149.20, the stock hit a new low of $131.20 in March 2026 before recovering to $153.00 -- essentially flat over 30 days but with extreme volatility ($121 low in Feb, $131 in March).

Both Seth Klarman (Baupost, 2.05% of portfolio at ~$173 avg cost) and Michael Burry (Scion, ~35% of portfolio) hold significant positions. The Q4 2025 earnings call (Feb 6, 2026) provided critical new information: a historic Florida CMS sole-source contract worth $6B annual premium, MAPD exit confirmation for 2027, and 2026 guidance of >= $5 adjusted EPS with embedded earnings of >$11/share.

The thesis remains intact but is now STRONGER than in March due to: (1) price tested $121-131 support twice and held, (2) management confirmed Medicaid is producing 2% pretax margin normalized, (3) Florida CMS contract is the largest single contract win in company history, and (4) Investor Day on May 8 should provide a detailed recovery roadmap.

Verdict: ACCUMULATE at current $153. Strong Buy below $135.

1. Business Model

What Molina Does

Molina Healthcare administers government-sponsored health insurance programs. It manages provider networks, processes claims, and assumes insurance risk on per-member-per-month (PMPM) premiums from state and federal governments.

Revenue Breakdown (FY 2025 Premium Revenue: $43.1B):

Segment Premium Revenue Members % of Total
Medicaid ~$34.4B 4.57M ~80%
Medicare ~$3.4B 262K ~8%
Marketplace (ACA) ~$5.3B 655K ~12%

2026 Guidance Shift:

  • Premium revenue: ~$42B (down slightly from 2025)
  • Marketplace being intentionally cut by ~50% (earnings accretive)
  • Florida CMS contract ramp begins late 2026 ($6B annual run rate)
  • Georgia and Texas new contracts ramping

How the Business Works

  1. State/Federal Government pays Molina a fixed PMPM premium, set via actuarial rate-setting
  2. Molina pays providers for members' healthcare via its managed care network
  3. The spread between premiums and medical costs is the MCR -- Molina's critical metric
  4. Molina's profit comes from keeping MCR below 88-89%, G&A ratio around 6.5%, plus investment income

The Medicaid Rate Cycle (KEY CONCEPT)

  1. Rates are set by states, typically annually, based on prior-year medical cost data
  2. When utilization surges, rates lag behind actual costs by 12-24 months
  3. Rates eventually catch up as states incorporate higher-cost data into actuarial rates
  4. Federal law requires "actuarial soundness" -- rates cannot be set below sustainable levels

Management estimates Medicaid is underfunded by 300-400 bps nationally. The Q4 2025 call provided the first positive signal: January rate cycle (60% of revenue) is "modestly in excess of trend."

2. What Changed Since March 15 Analysis

Price Action

Metric March 15 April 15 Change
Price $149.20 $153.00 +2.5%
Market Cap $7.68B $7.77B +1.2%
52-Week Low $121.06 $131.20 (new March low) Tested again
P/B 1.87x 1.91x Slight expansion

Key Developments Since March

  1. Stock tested $131 low in March -- bounced back to $153, establishing firmer base
  2. Q4 2025 earnings call clarity (Feb 6):
    • Florida CMS sole-source: $6B annual premium, go-live late 2026
    • MAPD exit confirmed for 2027
    • Embedded earnings now >$11/share (up from $8.65 at Q3)
    • Every 100 bps MCR improvement = ~$5/share
  3. Investor Day scheduled May 8, 2026 -- long-term goals and growth playbook
  4. Big Beautiful Bill passed -- Medicaid program changes being incorporated
  5. Marketplace intentional 50% premium reduction -- addition by subtraction

Geographic Footprint

Molina operates in ~20 states. Key contract wins:

  • Florida CMS sole-source: $6B annual premium, go-live late 2026 (largest single win ever)
  • Georgia Medicaid: ~$2B annual premium, ramping
  • Texas STAR+PLUS: New contract win
  • Wisconsin MyChoice LTSS: Renewed in Regions 2 and 7
  • RFP win rate: 90% renewal, 80% new -- industry leading

3. Competitive Position & Moat Assessment

Moat Type: Regulatory + Scale (Narrow to Moderate)

Moat Sources:

  1. Regulatory Barriers (Primary)

    • State Medicaid contracts require extensive licensure, actuarial capability, and provider network adequacy
    • RFP processes are long and complex; incumbency advantage is significant
    • State regulators prefer continuity -- disruption harms vulnerable populations
    • Multi-year contracts create revenue visibility (though rate resets add risk)

  2. Scale Efficiencies

    • G&A ratio of 6.5% is among the best in managed care
    • Spreading IT systems, compliance infrastructure, and actuarial teams across 5.5M members
    • Larger membership = better claims data = better risk management

  3. Operational Expertise

    • 44 years of Medicaid-focused operations since founding in 1980
    • Deep institutional knowledge of Medicaid populations (complex, high-acuity)
    • Track record of successfully onboarding new state contracts

Moat Weaknesses:

  • No pricing power: Rates are set by governments, not by Molina
  • Single payer risk: Government can change rules unilaterally
  • Low switching costs: Members are assigned, not choosing Molina voluntarily
  • Contract renewal risk: Contracts must be rebid periodically

Moat Width: NARROW -- Incumbent advantage is real but dependent on government policy. Not a wide moat like a Visa or Costco.

Competitive Landscape

Company Medicaid Members Focus
UnitedHealth (UNH) ~8M Diversified (Optum growth engine)
Centene (CNC) ~16M Largest Medicaid MCO, diversified
Elevance/Anthem (ELV) ~10M Blue Cross franchise, diversified
Molina (MOH) 4.6M Pure-play government, lowest G&A
CVS/Aetna ~3M Integrated pharmacy + care

Molina is smaller than peers but often cited as the most operationally efficient pure-play Medicaid MCO.

4. Financial Analysis

Income Statement Trends (5 Years)

Year Revenue Op Margin Net Margin EPS (Adj) ROE
2025 $45.4B 1.7% 1.0% $11.03 11.6%
2024 $40.7B 4.2% 2.9% $22.65 26.7%
2023 $34.1B 4.6% 3.2% $18.77 26.2%
2022 $32.0B 3.7% 2.5% $13.94 26.8%
2021 $27.8B 3.7% 2.4% $11.55 25.5%

Revenue CAGR (5yr): 10.3% -- Consistent double-digit growth driven by membership gains + rate increases + acquisitions.

Key Observation: 2025 was an aberration. Operating margins collapsed from a consistent 3.7-4.6% range to 1.7%, entirely driven by elevated MCR. The question is whether this is a one-off cyclical trough or a new normal.

Medical Care Ratios (The Critical Metric)

Period Medicaid Medicare Marketplace Consolidated
FY 2025 91.8% 92.4% 90.6% 91.7%
Q4 2025 93.5% 97.5% 99.0% 94.6%
FY 2024 ~90.0% ~88.3% ~74.0% ~89.5%
Target Range 88-89% 87-88% 73-75% ~88-89%

Q4 2025 was catastrophic across all segments. Key drivers:

  • Medicaid: Unfavorable retroactive premium rate actions in California (~$2.00/share impact)
  • Medicare: Elevated LTSS utilization + high-cost drugs (97.5% MCR = losing money)
  • Marketplace: Elevated utilization + prior-period provider claim settlements (99% MCR = breakeven)

Balance Sheet

Metric FY 2025 FY 2024
Total Assets $15.6B $15.6B
Stockholders' Equity $4.07B $4.50B
Cash & Investments $4.25B $4.66B
Total Debt $3.95B $3.12B
Net Debt ~$(0.3)B ~$(1.5)B
Debt/Equity 0.97 0.69
Book Value/Share $79.78 ~$85
Days Claims Payable 47 days N/A

Concern: Debt increased ~$830M in 2025, likely to fund operations during negative cash flow period and the ConnectiCare acquisition. Leverage has risen but remains manageable for an insurance company.

Cash Flow

Year Operating CF CapEx FCF Buybacks
2025 -$535M $101M -$636M $1,037M
2024 $644M $100M $544M $1,057M
2023 $1,662M $84M $1,578M $60M
2022 $773M $91M $682M $454M
2021 $2,119M $77M $2,042M $181M
5yr Average $933M $91M $842M $558M

FCF went negative in 2025 -- This is the scariest data point. Operating cash flow turned deeply negative while the company still spent $1B+ on buybacks. This was funded by debt. If 2026 cash flow doesn't recover, the buyback program must be curtailed.

However, context matters: Managed care cash flows are lumpy due to claims timing, medical loss reserve development, and premium payment timing. A single year of negative FCF after four years of strong positive FCF is not necessarily alarming.

5. Management Assessment

CEO: Joseph Zubretsky (since November 2017, 8+ years)

Track Record:

  • Inherited a struggling company with sub-par margins and governance issues (prior CEO Mario Molina was fired)
  • Revenue grew from ~$19B (2017) to $45.4B (2025) -- 2.4x growth
  • Stock price rose from ~$70 (2017) to peak of $424 (2024) -- 6x return before the selloff
  • Built aggressive acquisition pipeline (Magellan, ConnectiCare, Bright Health CA)
  • Maintained industry-best G&A ratio (~6.5%)

Compensation & Alignment:

  • Total comp ~$22M (7.3% salary, 92.7% stock-based)
  • Owns 298,910 shares (~$44.5M at current prices, 0.58% of company)
  • Red flag: All transactions in last 5 years have been sales, no purchases
  • Contract extended through 2027

Capital Allocation:

  • Aggressive share buybacks: $2.6B over 2022-2025 (reduced share count from ~58M to ~51M)
  • Continued buybacks even during negative FCF year (2025) -- questionable capital allocation
  • Acquisition-driven growth strategy with mixed results (ConnectiCare TBD, Bright Health MAPD underperforming)

Assessment: Good operator, questionable capital allocator in 2025. Buying back $1B of stock while operating cash flow was negative and funded by debt is not Buffett-quality capital allocation. However, his operational track record transforming Molina is undeniable.

6. Risk Analysis

Primary Risk: Medicaid Rate Underfunding (HIGH)

Management estimates Medicaid is underfunded by 300-400 bps nationally. While rates should eventually correct (actuarial necessity), the timing is uncertain. If states delay rate increases due to budget constraints, margins could remain compressed through 2027.

Secondary Risk: Government Policy (MODERATE-HIGH)

  • Medicaid funding cuts: Federal proposals to convert Medicaid to block grants or per-capita caps could fundamentally alter the business model
  • Enhanced subsidy expiration: ACA Marketplace enhanced subsidies may expire, potentially reducing Marketplace membership
  • CMS regulatory changes: Changes to managed care rules, MLR floors, or payment methodologies

Cyclicality: MODERATE

Medicaid managed care is counter-cyclical (membership grows in recessions) but margins are cyclical due to rate lag. Revenue is highly recession-resistant; profits are not.

Concentration Risk

  • Washington State = 13% of Medicaid premium revenue (single contract risk)
  • California retroactive rate action in Q4 2025 demonstrates state-level concentration risk
  • Florida new contract = $5B but implementation risk is high

Balance Sheet Risk: MODERATE

  • Debt increased 27% in 2025 ($3.12B to $3.95B)
  • Operating cash flow was negative in 2025
  • If 2026 FCF is also negative, debt servicing becomes a concern
  • However, $4.25B cash cushion provides buffer

Medicare Exit Risk: LOW-MODERATE

  • Exiting traditional MAPD in 2027 reduces diversification
  • $1.00/share drag in 2026 from underperforming MAPD business
  • Long-term positive (removes money-losing segment)

7. Valuation (Updated for $153)

Current Metrics

Metric Value Context
P/E (TTM, GAAP) ~32x Trough earnings, misleading
P/E (2026 guided, adj) 30.6x ($5.00) Trough, sandbagged
P/E (2026 underlying) 20.4x ($7.50) More realistic
P/E (normalized, $18-22) 7-8.5x Compelling
P/B 1.91x Below historical 3-4x
EV/EBITDA (2025) ~8x Reasonable
EV/Revenue 0.18x Extremely cheap
FCF Yield (5yr avg) 10.8% Attractive on normalized basis

Intrinsic Value Estimation (Revised)

Scenario 1: Full Recovery + Embedded Earnings (Bull, 40% probability)

  • 2028 EPS: $22-28 (base recovery + $11 embedded + rate normalization)
  • Apply 14-16x P/E
  • Fair Value: $308-$448
  • Upside: 101-193%

Scenario 2: Partial Recovery (Base Case, 45% probability)

  • 2028 EPS: $16-20 (moderate recovery, partial embedded harvest)
  • Apply 13-15x P/E
  • Fair Value: $208-$300
  • Upside: 36-96%

Scenario 3: Structural Impairment (Bear, 15% probability)

  • 2028 EPS: $8-12 (rates stuck below cost, policy headwinds)
  • Apply 10-12x P/E
  • Fair Value: $80-$144
  • Downside: 6-48%

Probability-Weighted Fair Value: $215-$290

Entry Prices (REVISED)

Level Price Implied P/E (Normalized $18) Margin of Safety
Strong Buy $135 7.5x 37-53%
Accumulate $153 (current) 8.5x 29-47%
Hold/Watch $180 10x 16-38%

WHY THE UPGRADE FROM WAIT TO ACCUMULATE:

  1. Price tested and held $121-131 support twice -- downside more defined
  2. Florida CMS contract worth $6B/year -- transformational growth
  3. Embedded earnings >$11/share -- up from $8.65 at Q3
  4. January rate cycle "modestly in excess of trend" -- first positive rate signal
  5. Investor Day May 8 -- near-term catalyst
  6. Klarman bought at $173 -- we are 10% below his entry
  7. Share count down 12% -- recovery EPS accrues to fewer shares

8. Why Burry and Klarman Are Buying

Michael Burry's Thesis (Scion Capital, ~35% of portfolio)

Burry compared Molina to "early GEICO" -- an insurer with superior operating efficiency trading at depressed prices during a cyclical trough. His key points:

  • Molina will "make money in Medicaid in 2026 while most competitors lose money"
  • Operational efficiency (low G&A) provides structural advantage during downturns
  • The stock is pricing in permanent impairment when the issue is temporary rate lag
  • Called it a "diamond in the rough"

Seth Klarman's Thesis (Baupost, 2.05% of portfolio)

Klarman initiated a $108M position (625,000 shares at ~$173 average cost) in Q4 2025:

  • Focus on "essential, recurring revenue streams"
  • Defensive healthcare positioning with "favorable regulatory dynamics and demographic tailwinds"
  • Alongside existing managed care holdings (Elevance Health)
  • Classic Klarman pattern: buying into forced selling and fear

What Their Convergence Signals

When two of the most disciplined value investors with very different styles (Burry = concentrated contrarian, Klarman = margin of safety absolutist) independently converge on the same stock at the same time, it strongly suggests:

  1. The selloff is creating genuine value, not a value trap
  2. The business is not structurally impaired
  3. The market is mispricing cyclical headwinds as permanent

9. Catalysts

Positive Catalysts

  1. Medicaid rate increases (2H 2026 - 2027): As states incorporate higher-cost data, rates should catch up to costs
  2. Florida contract ramp (2027+): Once implementation drag passes, $5B premium contract is highly accretive
  3. Georgia contract (~$2B annual premium): New market entry adds membership scale
  4. Medicare MAPD exit (2027): Removes money-losing segment, improves overall MCR
  5. Share buybacks at trough prices: If management buys back shares at $120-$150, it is extremely accretive vs. buying at $300+
  6. Industry consolidation: Molina is an attractive M&A target for larger MCOs

Negative Catalysts

  1. Federal Medicaid cuts: Block grant proposals or per-capita caps
  2. Delayed rate recovery: States slow to adjust rates due to budget constraints
  3. Another bad quarter: Q1 2026 miss could push stock to new lows
  4. ACA subsidy expiration: Marketplace membership could decline
  5. Balance sheet stress: Another year of negative FCF would be concerning

10. Investment Thesis (UPGRADED)

Molina Healthcare at $153 represents a compelling opportunity to buy a pure-play government managed care operator at 8.5x normalized earnings, with >$11/share of contracted embedded earnings, at prices 10% below where Seth Klarman established his position. The business serves 5.5 million low-income Americans with recession-resistant, counter-cyclical revenue.

The margin trough is real but temporary. Management confirmed Medicaid produces 2% pretax margin normalized at the trough, January rates are "modestly in excess of trend" (first positive signal), and embedded earnings from Florida ($6B), Georgia ($2B), Texas, and Medicare duals exceed $11/share. The share count has been reduced 12% through buybacks, amplifying recovery EPS.

The upgrade from WAIT to ACCUMULATE reflects: (1) price tested $121-131 support twice and held; (2) Florida CMS sole-source contract is transformational; (3) embedded earnings rose to >$11/share; (4) Investor Day May 8 is an approaching catalyst; and (5) fewer shares mean higher recovery EPS.

Recommendation: ACCUMULATE at $153. Strong Buy below $135. Target allocation 2-4%.

Key risks remain: federal Medicaid policy changes, rate recovery timing, Florida execution. But at sub-2x book with $4.25B cash, Klarman and Burry as co-investors, and a probability-weighted fair value of $215-$290, the risk/reward is favorable for patient investors willing to hold through a 2026 trough year.

Expected holding period: 2-3 years for full thesis realization ($250-$350+ as margins normalize and embedded earnings are harvested).

Appendix: Key Financial Data

Quarterly EPS Trend (Last 8 Quarters)

Quarter Revenue GAAP EPS Adj EPS MCR
Q4 2025 $11.38B -$3.15 -$2.75 94.6%
Q3 2025 $11.48B $1.51 $1.84 92.6%
Q2 2025 $11.43B $4.75 $5.48 90.3%
Q1 2025 $11.15B $5.45 $6.08 89.7%
Q4 2024 $10.50B $4.44 $5.05 90.2%
Q3 2024 $10.34B $5.65 $6.01 89.2%
Q2 2024 $9.88B $5.17 $5.86 89.8%
Q1 2024 $9.93B $5.17 $5.73 89.0%

2026 Guidance Summary

Metric 2026 Guidance
Premium Revenue $42.2B (-2% vs 2025)
GAAP EPS >= $3.20
Adjusted EPS >= $5.00
Consolidated MCR 92.6%
Medicaid MCR 92.9%
Medicare MCR 94.0%
Marketplace MCR 85.5%
G&A Ratio (Adj) 6.4%

Share Count Reduction

Year Diluted Shares (M) Buybacks
2025 52.9M $1,037M
2024 56.5M $1,057M
2023 58.6M $60M
2022 57.8M $454M
2021 58.4M $181M

Data Sources: AlphaVantage API (financial statements, earnings transcripts -- April 2026 refresh), Molina Healthcare Q4 2025 & Q3 2025 earnings calls, EODHD (historical prices). Analysis refreshed April 15, 2026.